Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

被引：0
|
作者：
Antonio Pérez
Pedro Mezquita Raya
Antonio Ramírez de Arellano
Teresa Briones
Barnaby Hunt
William J. Valentine
机构：
[1] Hospital de la Santa Creu i Sant Pau,
[2] Hospital Torrecardenas,undefined
[3] Clinica San Pedro,undefined
[4] Novo Nordisk,undefined
[5] Ossian Health Economics and Communications,undefined
来源：
Diabetes Therapy | 2015年 / 6卷
关键词：
Cost; Cost-effectiveness; Incretin; Liraglutide; Sitagliptin; Spain; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：61 / 74
页数：13
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
    Perez, Antonio
    Mezquita Raya, Pedro
    Ramirez de Arellano, Antonio
    Briones, Teresa
    Hunt, Barnaby
    Valentine, William J.
    [J]. DIABETES THERAPY, 2015, 6 (01) : 61 - 74
  • [2] Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
    Mezquita Raya, Pedro
    Perez, Antonio
    Ramirez de Arellano, Antonio
    Briones, Teresa
    Hunt, Barnaby
    Valentine, William J.
    [J]. DIABETES THERAPY, 2013, 4 (02) : 417 - 430
  • [3] Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
    Pedro Mezquita Raya
    Antonio Pérez
    Antonio Ramírez de Arellano
    Teresa Briones
    Barnaby Hunt
    William J. Valentine
    [J]. Diabetes Therapy, 2013, 4 : 417 - 430
  • [4] INCRETIN THERAPY FOR PATIENTS WITH TYPE 2 DIABETES IN SPAIN: A COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN
    Ramirez de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [5] COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
    Ramirz de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A249 - A250
  • [6] COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE 1.8MG VERSUS LIXISENATIDE 20μG FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ITALY
    Kragh, N.
    Ye, E.
    Valentine, W. J.
    Hunt, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [7] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [8] EVALUATING THE COST-EFFECTIVENESS OF LIRAGLUTIDE 1.8MG VERSUS LIXISENATIDE 20μG FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE SPANISH SETTING
    Kragh, N.
    Ye, E.
    Hunt, B.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
  • [9] Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
    Tzanetakos, Charalampos
    Melidonis, Andreas
    Verras, Christos
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. BMC HEALTH SERVICES RESEARCH, 2014, 14
  • [10] COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN OR EXENATIDE IN PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON ORAL ANTIDIABETIC DRUGS IN GREECE
    Tzanetakos, C.
    Melidonis, A.
    Verras, C.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
12345